Abelha Pereira Filipa, Miranda Diana Oliveira, Alvarenga José Miguel, Correia Ana Lucinda
Internal Medicine, Santo António University Hospital Center, Porto, PRT.
Dermatology, Santo António University Hospital Center, Porto, PRT.
Cureus. 2024 Nov 2;16(11):e72889. doi: 10.7759/cureus.72889. eCollection 2024 Nov.
Pregnancy- and lactation-associated osteoporosis (PLO) is a rare condition that affects women during pregnancy or postpartum. We report the case of a 29-year-old woman who experienced severe lower back pain 11 weeks after childbirth, revealing multiple compressive vertebral fractures in imaging studies. Despite no identifiable risk factors, the patient underwent an assessment ruling out secondary causes of osteoporosis, with only vitamin D deficiency and expected alterations in bone biomarkers identified. Treatment involved chemically suppressing lactation, along with calcium and vitamin D supplementation. After three months of follow-up, vitamin D levels and bone biomarkers normalized, but the pain persisted, and bone mineral density decreased. The literature review underscores the lack of understanding regarding PLO's etiology and pathophysiology. Possible causes include genetic factors, alterations in calcium metabolism, and abnormalities in calcium transfer adaptation from the mother to the fetus. Treatment lacks standardization, but calcium and vitamin D supplementation are common. Therapies such as bisphosphonates, teriparatide, calcitonin, denosumab, and strontium ranelate have been evaluated, considering their effectiveness and safety. Due to the initial lack of improvement, teriparatide was initiated in this case. In conclusion, PLO poses a diagnostic challenge due to its low incidence and lack of comprehension of underlying mechanisms. Early diagnosis, personalized treatment, and strict monitoring are crucial for improving the prognosis of these patients.
妊娠和哺乳期相关骨质疏松症(PLO)是一种罕见的病症,会影响孕期或产后的女性。我们报告了一例29岁女性病例,该患者在分娩后11周出现严重的下背部疼痛,影像学检查显示多处椎体压缩性骨折。尽管没有可识别的风险因素,但患者接受了评估,排除了骨质疏松症的继发性病因,仅发现维生素D缺乏以及骨生物标志物的预期变化。治疗包括化学抑制泌乳,同时补充钙和维生素D。经过三个月的随访,维生素D水平和骨生物标志物恢复正常,但疼痛持续存在,骨密度下降。文献综述强调了对PLO病因和病理生理学缺乏了解。可能的原因包括遗传因素、钙代谢改变以及母体向胎儿钙转运适应异常。治疗缺乏标准化,但补充钙和维生素D很常见。考虑到双膦酸盐、特立帕肽、降钙素、地诺单抗和雷奈酸锶等疗法的有效性和安全性,已对其进行了评估。由于最初没有改善,本病例开始使用特立帕肽。总之,由于PLO发病率低且对其潜在机制缺乏了解,因此构成了诊断挑战。早期诊断、个性化治疗和严格监测对于改善这些患者的预后至关重要。